---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-091099"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2026-08-05T20:11:23+00:00"
generated_at: "2026-08-05T20:13:45.396152+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Protagonist Q2 net income $162.8M; ICOTYDE launch, rusfertide PDUFA in Aug 2026

## Summary
- Q2 2026 net income $162.8M ($2.47 basic EPS) vs net loss $34.8M in Q2 2025; revenue $213.5M from Takeda opt-out and J&J milestones.
- ICOTYDE (icotrokinra) first full quarter of commercial sales; FDA approved Mar 2026; J&J partnership with up to $580M milestones and 6-10% royalties.
- Rusfertide NDA under priority review for polycythemia vera; PDUFA date Aug 2026; Takeda opt-out triggered $200M payment, additional $200M and $75M upon approval.
- PN-881 (oral IL-17 antagonist) Phase 2b psoriasis program planned early Q1 2027; PN-477sc (triple agonist) Phase 1 initiated.
- Cash $849.5M as of June 30, 2026; potential share buyback program announcement by year-end.

## SEC filing metadata
- accession: 0001104659-26-091099
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2026-08-05T20:11:23+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/0001104659-26-091099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-091099
- JSON: https://secwatch.observer/filing/0001104659-26-091099.json
- Plain text: https://secwatch.observer/filing/0001104659-26-091099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.